Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis

    Basic Details
    Date Posted
    Friday, June 24, 2022
    Status
    Complete
    Medical Product
    bamlanivimab
    bamlanivimab etesevimab
    casirivimab imdevimab
    Health Outcome(s)
    utilization
    Description

    In this report we examined counts of individuals using the monoclonal antibodies (mAbs) under an Emergency Use Authorization (EUA) in the Rapid Coronavirus Disease 2019 (COVIDÔÇÉ19) Sentinel Distributed Database (SDD).

    The study period includes data from November 1, 2020 to January 31, 2021. We distributed this request to three Sentinel Data Partners on July 28, 2021.

    Additional Details
    FDA Center
    CDER
    Time Period
    November 1, 2020 - January 31, 2021
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)